Note 14 - Strategic Alliances (Details Textual) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended			6 Months Ended		25 Months Ended	39 Months Ended
	Mar. 16, 2025	Mar. 08, 2023	Sep. 14, 2021	Jun. 18, 2021	May 05, 2020	Sep. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Mar. 31, 2023	Jun. 30, 2025	Jun. 30, 2024	Mar. 31, 2025	Mar. 31, 2025	Jan. 07, 2025	Dec. 31, 2024	Sep. 29, 2024	Oct. 01, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to Acquire Investments										$ 7,665	$ 0
Revenue from Contract with Customer, Excluding Assessed Tax							$ 156,807	$ 182,186		306,759	355,872
Corporate Joint Venture [Member] \| LeaderMed Joint Venture [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 1,000
Subsidiary, Ownership Percentage, Parent			47.00%
LeaderMed [Member] \| Corporate Joint Venture [Member] \| LeaderMed Joint Venture [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to Acquire Interest in Joint Venture			$ 11,000
Subsidiary, Ownership Percentage, Noncontrolling Owner			53.00%
Collaboration and License Agreement With Entera [Member] \| Entera Ordinary Shares [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment Owned, Shares Purchased (in shares)	3,685,226
Shares Purchased, Price Per Share (in dollars per share)	$ 2.17
Payments to Acquire Investments	$ 8,000
Collaboration and License Agreement With Entera [Member] \| Opko [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership, Percentage	60.00%
Collaboration and License Agreement With Entera [Member] \| Opko [Member] \| Entera Discontinuing Funding [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership, Percentage	85.00%
Collaboration and License Agreement With Entera [Member] \| Entera [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership, Percentage	40.00%
Collaboration and License Agreement With Entera [Member] \| Entera [Member] \| Entera Discontinuing Funding [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership, Percentage	15.00%
BARDA Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangement, Supplement for Advance of Development						$ 26,900
Revenue from Contract with Customer, Excluding Assessed Tax						24,100	6,500	$ 5,000		13,500	$ 7,200
Collaborative Arrangement, Value						110,000										$ 59,000
Collaborative Arrangement, Value, Including Milestones						$ 205,000										$ 168,600
Aggregate Transaction Price Allocated to Remaining Performance Obligations, Excluding Unexercised Contract Options, Amount										71,600
Merck Agreement [Member] \| Merck Sharp & Dohme LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 50,000
Collaborative Arrangement, Development Milestone Payment		$ 860,000												$ 12,500
Collaborative Arrangement, Development Costs												$ 26,500
Development and License Agreement [Member] \| NICOYA Macau Limited [Member] \| EirGen [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 5,000					$ 2,500
Collaborative Arrangement, Development Milestone Payment				115,000
Collaborative Agreement, Delayed Payment				$ 5,000
Collaborative Agreement, Delayed Payment Received, Cumulative									$ 2,500
Collaborative Arrangement, Period Following First Commercial Sale (Year)				10 years
Development and License Agreement [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| EirGen [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangement, Maximum Regulatory Milestone Payments					$ 15,000
Collaborative Arrangement, Sales Milestone Payment					200,000
Collaborative Agreement, Option, Sales Milestone Payments					555,000
Development and License Agreement [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| EirGen [Member] \| First Marketing Approval of Rayaldee in Europe [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax					3,000
Development and License Agreement [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| EirGen [Member] \| Germany Price Approval by Local Sick Fund Association [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax					$ 7,000
Pfizer Agreement [Member] \| Pfizer Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax													$ 175,000
Collaborative Arrangement, Maximum Regulatory Milestone Payments																	$ 275,000
Revenue, Remaining Performance Obligation, Amount																	295,000
Contract with Customer, Liability							$ 0			$ 0					$ 0
Pfizer Agreement [Member] \| Pfizer Inc. [Member] \| Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Agreements, Each Milestone Payment																	20,000
Pfizer Agreement [Member] \| Pfizer Inc. [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Agreements, Each Milestone Payment																	$ 90,000

OPKO HEALTH, INC. 10-Q